Abstract

Congenital hypodysfibrinogenemia is a rare fibrinogen disorder, defined by decreased levels of a dysfunctional fibrinogen. We present the functional and structural characterization of two new fibrinogen variants. A duplication of 32 bases in FGA exon 5, p.Ser382GlyfsTer50 was identified in a patient (P1) with history of hemoptysis and traumatic cerebral bleeding. A missense mutation in FGG exon 8, p.Ala353Ser was identified in two siblings (P2 and P3) with tendency to bruising and menorrhagia. Fibrin polymerization was studied in plasma and in purified fibrinogen by turbidimetry. Fibrin structure was studied by a permeability assay, laser scanning confocal microscopy (LSCM) and scanning electron microscopy (SEM). In both plasma and purified fibrinogen samples, all patients had an abnormal polymerization characterized by a decreased maximal absorption compared to controls. The permeation constant (Ks) was markedly increased in all patients: 31 ± 9 × 10−9 cm2 in P1, and 20 ± 0.1 × 10−9 cm2 in P2 and P3, compared to 6 ± 2 × 10−9 cm2 in the control (p < 0.05). The presence of very large pores that accounts for the increased Ks was confirmed by LSCM and SEM patients' clots images. By SEM, the patients' fibrin fibers diameters were thicker: 90 ± 25 nm in P1, 162 ± 64 nm in P2 and 132 ± 46 nm in P3 compared to 74 ± 25 nm in control (p < 0.0001). In conclusion, both new causative fibrinogen mutations altered clot structure by forming thick fibers, diminishing fiber branching, and increasing pore filling space. These structural changes to clots explain the patients' bleeding phenotypes.

Highlights

  • Fibrinogen is one of the most abundant plasma proteins with a normal concentration of 2–4 g/L [1]

  • Diagnosis of hypodysfibrinogenemia was made according to the recent guidelines [12]

  • D-dimer value was 199.93 ng/mL in P1. He reported a bleeding phenotype, charac­ terized by an episode of minor hemoptysis and an episode of traumatic intracranial bleeding treated by surgery without fibrinogen supple­ mentation

Read more

Summary

Introduction

Fibrinogen is one of the most abundant plasma proteins with a normal concentration of 2–4 g/L [1]. The fibrinopeptides A and B (FpA and FpB) comprising the N-terminal ends of the Aα and Bβ chains respectively, are cleaved by thrombin at Aα Arg35(16) and Bβ Arg44(14) when coagulation is activated [3] These proteolytically modified fibrinogen molecules aggregate in a sequential and ordered manner forming a network stabilized by activated factor XIII (FXIIIa) [6]. Other cases are due to heterozygosity for a single mutation which leads to synthesis of an abnormal fibrinogen molecule that is secreted less efficiently than normal fibrinogen. Most of the latter mutations are clustered in FGG [14]. Patients with hypodysfibrinogenemia can suffer from a broad range of symptoms, from major bleeding to thrombosis and their clinical course is often unpredictable [14]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call